An evaluation of eptacog alfa in nonhaemophiliac conditions

Drugs

Volumn 68, Issue 12, 2008, Pages 1665-1689

  Mallarkey, Gordon ^a   Brighton, Tim ^b   Thomson, Amanda ^c   Kaye, Karen ^a   Seale, Paul ^d   Gazarian, Madlen ^e  

^a New South Wales Therapeutic Advisory Group   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cerebral haemorrhage, treatment; Children; Drug interactions; Eptacog alfa, therapeutic use; Haemorrhage, treatment; Surgery; Warfarin, drug interactions

Indexed keywords

FONDAPARINUX; IDRAPARINUX; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; VITAMIN K GROUP; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; BLUNT TRAUMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONSENSUS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; EMBASE; FOOD AND DRUG ADMINISTRATION; HEART MUSCLE ISCHEMIA; HEART SURGERY; HEMOSTASIS; HUMAN; INJURY; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; LUNG EMBOLISM; MEDLINE; MORTALITY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT SELECTION; PENETRATING TRAUMA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; VEIN THROMBOSIS;

FACTOR VIIA; HEMORRHAGE; HUMANS; LIVER DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RISK ASSESSMENT; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 49149099325     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868120-00005     Document Type: Review

References (127)

1. Gazarian M, Kelly M, McPhee JR, et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2006 Nov 20; 185 (10): 544-8
2. NHMRC. NHMRC additional levels of evidence and grades for recommendations for developers of guidelines [online]. Available from URL: http://www.nhmrc. gov.au 2005 [Accessed 2006 Dec 18]
3. Stanworth SJ, Birchall J, Doree CJ, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2007; (2): CD005011
4. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33 (4): 883-90
5. Shander A, Goodnough LT, Ratko T, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven) therapy. Pharm Ther 2005; 30 (11): 644-58
6. Selin S, Tejani A. Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders [issues in emerging health technologies issue 82]. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment, 2006
7. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352 (8): 777-85
8. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma Inj Infect Crit Care 2005; 59 (1): 8-18
9. Vincent JL, Rossaint R, Riou B, et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding: a European perspective. Crit Care 2006; 10 (4): R120
10. Rudisill CN, Hockman RH, Degregory KA, et al. Implementing guidelines for the institutional use of factor VIIa (recombinant): a multidisciplinary solution. Am J Health Syst Pharm 2006 Sep 1; 63 (17): 1641-6
11. Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 3 (4): 640-8
12. Gliklich RE, Dreyer NA, editors. Registries for evaluating patient outcomes: a user's guide - 2007. Prepared by Outcome DEcIDE Center (Outcome Sciences, Inc. dba Outcome) under Contract No. HHSA29020050035I TO1 [online]. Available from URL: http://effectivehealthcare.ahrq.gov/healthInfo.cfm?. infotype=nr&ProcessID=21&DocID=11 [Accessed 2008 Mar 29]
13. Isbister J, Phillips L, Dunkley S, et al. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register. Intern Med J 2008 Mar; 38 (3): 156-65
14. O'Connell NM, Perry DJ, Hodgson AJ, et al. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 2003; 43 (12): 1711-6
15. Grounds RM, Seebach C, Knothe C, et al. Use of recombinant activated factor VII (Novoseven) in trauma and surgery: analysis of outcomes reported to an international registry. J Intensive Care Med 2006; 21 (1): 27-39
16. Brenner B, Hoffman R, Balashov D, et al. Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb Hemost 2005; 11 (4): 401-10
17. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004 Oct; 127 (4): 1123-30
18. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997 Dec; 113 (6): 1930-7
19. Ganguly S, Spengel K, Tilzer LL, et al. Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome. Clin Lab Haematol 2006; 28 (5): 309-12
20. Romero-Castro R, Jimenez-Saenz M, Pellicer-Bautista F, et al. Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices. Clin Gastroenterol Hepatol 2004; 2 (1): 78-84
21. Anantharaju A, Mehta K, Mindikoglu AL, et al. Use of activated recombinant human factor VII (rhFVIIa) for colonic polypectomies in patients with cirrhosis and coagulopathy. Dig Dis Sci 2003; 48 (7): 1414-24
22. da Silva Viana J. Recombinant factor VIIa in major abdominal surgery and liver transplantation. Transplant Proc 2006; 38 (3): 818-9
23. Lodge JPA, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transplant 2005; 11 (8): 973-9
24. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transplant 2005; 11 (8): 895-900
25. Lodge JPA, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005; 102 (2): 269-75
26. Shao YF, Yang JM, Chau GY, et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg 2006; 191 (2): 245-9
27. Niemann CU, Behrends M, Quan D, et al. Recombinant factor VIIa reduces transfusion requirements in liver transplant patients with high MELD scores. Transfus Med 2006; 16 (2): 93-100
28. Pavese P, Bonadona A, Beaubien J, et al. FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases. Can J Anaesth 2005; 52 (1): 26-9
29. Gala B, Quintela J, Aguirrezabalaga J, et al. Benefits of recombinant activated factor VII in complicated liver transplantation. Transplant Proc 2005; 37 (9): 3919-21
30. Tanos M, Dunning J. Is recombinant activated factor VII useful for intractable bleeding after cardiac surgery? Interact Cardiovasc Thorac Surg 2006; 5 (4): 493-8
31. Warren O, Mandal K, Hadjianastassiou V, et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 2007; 83 (2): 707-14
32. Diprose P, Herbertson MJ, O'Shaughnessy DO, et al. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005; 95 (5): 596-602
33. Ma B, Wang ZN, Zhang BR, et al. Effect of recombinant activated factor VII a on early recovery of patients undergoing cardiac valve replacement under cardiopulmonary bypass: a randomized double-blind placebo-controlled trial [abstract; in Chinese]. Dier Junyi Daxue Xuebao 2006; 27 (10): 1110-3
34. McCall P, Story DA, Karapillai D. Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery. Can J Anaesth 2006 Sep; 53 (9): 926-33
35. Walsham J, Fraser JF, Mullany D, et al. The use of recombinant activated factor VII for refractory bleeding post complex cardiothoracic surgery. Anaesth Intensive Care 2006; 34 (1): 13-20
36. van de Garde EMW, Bras LJ, Heijmen RH, et al. Low-dose recombinant factor VIIa in the management of uncontrolled postoperative hemorrhage in cardiac surgery patients. J Cardiothorac Vasc Anesth 2006; 20 (4): 573-5
37. Romagnoli S, Bevilacqua S, Gelsomino S, et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 2006; 102 (5): 1320-6
38. Tritapepe L, De Santis V, Vitale D, et al. Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis. Crit Care Med 2007 Jul; 35 (7): 1685-90
39. Raobaikady R, Redman J, Ball JAS, et al. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth 2005; 94 (5): 586-91
40. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361 (9353): 201-5
41. McMullin NR, Kauvar DS, Currier HM, et al. The clinical and laboratory response to recombinant factor VIIa in trauma and surgical patients with acquired coagulopathy. Curr Surg 2006; 63 (4): 246-51
42. Payne EM, Brett SJ, Laffan MA. Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience. Blood Coagul Fibrinolysis 2006; 17 (5): 397-402
43. Tawfick WA, Tawfik S, Hynes N, et al. Critical bleeding in vascular surgery: expanding the indication of recombinant activated factor VII. Vascular 2006; 14 (1): 32-7
44. Pape HC, Erhardtsen E, Meyer C, et al. Recombinant factor VIIa for life-threatening hemorrhage in trauma patients: review of the literature. Eur J Trauma 2006; 32 (5): 439-48
45. Spivey M, Parr MJ. Therapeutic approaches in trauma-induced coagulopathy. Minerva Anestesiol 2005 Jun; 71 (6): 281-9
46. Rosenfeld JV, Kossmann T. New haemostatic agents, blood substitutes and the implications for military medicine. ADF Health 2005; 5: 59-63
47. Webert KE, Blajchman MA. Randomized trials in patients with blunt and penetrating trauma. J Trauma 2006 Jan; 60 (1): 242-3; author reply 243-4
48. Johansson PI, Eriksen K, Nielsen SL, et al. Recombinant FVIIa decreases perioperative blood transfusion requirement in burn patients undergoing excision and skin grafting: results of a single centre pilot study. Burns 2007 Jun; 33 (4): 435-40
49. Rizoli SB, Nascimento Jr B, Osman F, et al. Recombinant activated coagulation factor VII and bleeding trauma patients. J Trauma Inj Infect Crit Care 2006; 61 (6): 1419-25
50. Perkins JG, Schreiber MA, Wade CE, et al. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion. J Trauma 2007 May; 62 (5): 1095-9; discussion 9-101
51. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004 Oct; 57 (4): 709-18; discussion 18-9
52. Harrison TD, Laskosky J, Jazaeri O, et al. 'Low-dose' recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. J Trauma Inj Infect Crit Care 2005; 59 (1): 150-4
53. Geeraedts Jr LMG, Kamphuisen PW, Kaasjager HAH, et al. The role of recombinant factor VIIa in the treatment of life-threatening haemorrhage in blunt trauma. Injury 2005; 36 (4): 495-500
54. Gowers CJD, Parr MJA. Recombinant activated factor VIIa use in massive transfusion and coagulopathy unresponsive to conventional therapy. Anaesth Intensive Care 2005; 33 (2): 196-200
55. Udy A, Vaghela M, Lawton G, et al. The use of recombinant activated factor VII in the control of haemorrhage following blunt pelvic trauma. Anaesthesia 2005; 60 (6): 613-6
56. Mayer SA. Ultra-early hemostatic therapy for primary intracerebral hemorrhage: a review. Can J Neurol Sci 2005; 32 Suppl. 2: S31-7
57. Mayer SA, Rincon F. Ultra-early hemostatic therapy for acute intracerebral hemorrhage. Semin Hematol 2006; 43 Suppl. 1: S70-6
58. Mayer SA, Brun NC, Broderick J, et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005; 36 (1): 74-9
59. Mayer SA, Brun NC, Broderick J, et al. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. Neurocritic Care 2006; 4 (3): 206-14
60. Mayer SA, Brun NC, Begtrup K, et al. Randomized, placebo-controlled, double-blind phase III study to assess rFVIIa efficacy in acute cerebral haemorrhage: the FAST trial [abstract]. XVI European Stroke Conference; 2007 29 May-1 Jun; Glasgow
61. Cassels C. FAST trial shows no benefit of Factor VII in treatment of ICH 2007 [online]. Available from URL: http://www.medscape.com/viewarticle/557558?. rss [Accessed 2007 Aug 8]
62. Erhardtsen E, Nony P, Dechavanne M, et al. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998 Nov; 9 (8): 741-8
63. Sorensen BB, Hedner U, Erhardtsen E. rFVIIai in acute coronary syndromes. Semin Vasc Med 2003; 3 (2): 199-204
64. Deveras RAE, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137 (11): 884-8
65. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004 Dec; 79 (12): 1495-500
66. Talkad A, Mathews M, Honings D, et al. Reversal of warfarin-induced anticoagulation with factor VIIa prior to rt-PA in acute stroke. Neurology 2005; 64 (8): 1480-1
67. Udvardy M, Telek B, Mezey G, et al. Successful control of massive coumarol-induced acute upper gastrointestinal bleeding and correction of prothrombin time by recombinant active factor VII (Eptacog-alpha, NovoSeven) in a patient with a prosthetic aortic valve and two malignancies (chronic lymphoid leukaemia and lung cancer). Blood Coagul Fibrinolysis 2004; 15 (3): 265-7
68. Brody DL, Aiyagari V, Shackleford AM, et al. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocritic Care 2005; 2 (3): 263-7
69. Roitberg B, Emechebe-Kennedy O, Amin-Hanjani S, et al. Human recombinant factor VII for emergency reversal of coagulopathy in neurosurgical patients: a retrospective comparative study. Neurosurgery 2005; 57 (5): 832-5
70. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106 (20): 2550-4
71. Bijsterveld NR, Vink R, Van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004; 124 (5): 653-8
72. Berntorp E, Stigendal L, Lethagen S, et al. NovoSeven in warfarin-treated patients. Blood Coagul Fibrinolysis 2000 Apr; 11 Suppl. 1: S113-5
73. Wolzt M, Levi M, Sarich TC, et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost 2004; 91 (6): 1090-6
74. Huvers F, Slappendel R, Benraad B, et al. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med 2005; 63 (5): 184-6
75. Michalska-Krzanowska G, Czuprynska M. Recombinant factor VII (activated) for haemorrhagic complications of severe sepsis treated with recombinant protein C (activated). Acta Haematol 2006; 116 (2): 126-30
76. Mathew P, Young G. Recombinant factor VIIa in paediatric bleeding disorders: a 2006 review. Haemophilia 2006; 12 (5): 457-72
77. Tobias JD, Berkenbosch JW. Synthetic factor VIIa concentrate to treat coagulopathy and gastrointestinal bleeding in an infant with end-stage liver disease. Clin Pediatr (Phila) 2002 Oct; 41 (8): 613-6
78. Chuansumrit A, Treepongkaruna S, Phuapradit P. Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost 2001 Apr; 85 (4): 748-9
79. Young G, Nugent DJ. Prevention of bleeding complications in neonates with liver failure undergoing surgery using recombinant factor VIIa. Hematology 2001 2001; 6: 341-6
80. Pettersson M, Fischler B, Petrini P, et al. Recombinant FVIIa in children with liver disease. Thromb Res 2005; 116 (3): 185-97
81. Atkinson PR, Jardine L, Williams S, et al. Use of recombinant factor VIIa in pediatric patients with liver failure and severe coagulopathy. Transplant Proc 2005; 37: 1091-3
82. Kalicinski P, Markiewicz M, Kaminski A, et al. Single pretransplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation. Pediatr Transplant 2005 Jun; 9 (3): 299-304
83. Markiewicz M, Kalicinski P, Kaminski A, et al. Acute coagulopathy after reperfusion of the liver graft in children correction with recombinant activated factor VII. Transplant Proc 2003; 35 (6): 2318-9
84. Alioglu B, Avci Z, Baskin E, et al. Successful use of recombinant factor VIIa (NovoSeven) in children with compartment syndrome: two case reports. J Ped Orthoped 2006; 26 (6): 815-7
85. Ekert H, Brizard C, Eyers R, et al. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions. Blood Coagul Fibrinolysis 2006; 17 (5): 389-95
86. Al Douri M, Shafi T, Al Khudairi D, et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000 Apr; 11 Suppl. 1: S121-7
87. Leibovitch L, Kenet G, Mazor K, et al. Recombinant activated factor VII for life-threatening pulmonary hemorrhage after pediatric cardiac surgery. Pediatr Crit Care Med 2003 Oct; 4 (4): 444-6
88. Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med 2003 Jan; 4 (1): 49-51
89. Pychynska-Pokorska M, Moll JJ, Krajewski W, et al. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med 2004 May; 5 (3): 246-50
90. Razon Y, Erez E, Vidne B, et al. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Paediatr Anaesth 2005 Mar; 15 (3): 235-40
91. Tobias JD, Simsic JM, Weinstein S, et al. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients. J Intensive Care Med 2004 Sep-Oct; 19 (5): 270-3
92. Agarwal HS, Bennett JE, Churchwell KB, et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg 2007 Jul; 84 (1): 161-8
93. Mitsiakos G, Papaioannou G, Giougi E, et al. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases. J Pediatr Hematol Oncol 2007 Mar; 29 (3): 145-50
94. Olomu N, Kulkarni R, Manco-Johnson M. Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants. J Perinatol 2002 Dec; 22 (8): 672-4
95. Veldman A, Josef J, Fischer D, et al. A prospective pilot study of prophylactic treatment of preterm neonates with recombinant activated factor VII during the first 72 hours of life. Pediatric Crit Care Med 2006; 7 (1): 34-9
96. Robertson JD. Prevention of intraventricular haemorrhage: a role for recombinant activated factor VII? J Paediatr Child Health 2006; 42 (6): 325-31
97. Brady KM, Blaine Easley R, Tobias JD. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage. Paediatr Anaesth 2006; 16 (10): 1042-6
98. Hunseler C, Kribs A, Eifinger F, et al. Recombinant activated factor seven in acute life-threatening bleeding in neonates: report on three cases and review of literature. J Perinatol 2006; 26 (11): 706-13
99. Morenski JD, Tobias JD, Jimenez DF. Recombinant activated factor VII for cerebral injury-induced coagulopathy in pediatric patients: report of three cases and review of the literature. J Neurosurg 2003; 98 (3): 611-6
100. Kulkarni R, Daneshmand A, Guertin S, et al. Successful use of activated recombinant factor VII in traumatic liver injuries in children. J Trauma Inj Infect Crit Care 2004; 56 (6): 1348-52
101. Millar CG, Stringer MD, Sugarman I, et al. The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia 2005; 11 (2): 171-4
102. Wittenstein B, Ng C, Ravn H, et al. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatric Crit Care Med 2005; 6 (4): 473-6
103. Dominguez TE, Mitchell M, Friess SH, et al. Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation. Pediatric Crit Care Med 2005; 6 (3): 348-51
104. López-Herce Cid J, Arriola Pereda G, Zunzunegui Martínez JL, et al. Effectiveness of activated factor VII in postoperative bleeding after cardiac surgery with extracorporeal membrane oxygenation [in Spanish]. An Pediatr (Barc) 2005; 62 (5): 471-4
105. Kolban M, Balachowska-Kosciolek I, Chmielnicki M. Recombinant coagulation factor VIIa: a novel haemostatic agent in scoliosis surgery? Eur Spine J 2006; 15 (6): 944-52
106. Chuansumrit A, Wangruangsatid S, Lektrakul Y, et al. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis 2005; 16 (8): 549-55
107. Chuansumrit A, Tangnararatchakit K, Lektakul Y, et al. The use of recombinant activated factor VII for controlling life-threatening bleeding in Dengue Shock Syndrome. Blood Coagul Fibrinolysis 2004; 15 (4): 335-42
108. Roberts HR, Monroe ID, Hoffman M. safety profile of recombinant factor VIIa. Sem Hematol 2004; 41 (1 Suppl. 1): 101-8
109. Kluger Y, Riou B, Rossaint R, et al. Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial. Crit Care 2007; 11 (4): R85
110. Diringer MN, Skolnick BE, Mayer SA, et al. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke 2008 Mar; 39 (3): 850-6
111. Karkouti K, Yau TM, Riazi S, et al. Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Can J Anaesth 2006 Aug; 53 (8): 802-9
112. Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005; 45 (1): 26-34
113. Levy JH, Fingerhut A, Brott T, et al. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion 2006; 46 (6): 919-33
114. Thomas GO, Dutton RP, Hemlock B, et al. Thromboembolic complications associated with factor VIIa administration. J Trauma 2007 Mar; 62 (3): 564-9
115. Subramaniam S, Demchuk AM, Watson T, et al. Unexpected posthemorrhagic hydrocephalus in patients treated with rFVIIa. Neurology 2006; 67 (6): 1096
116. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295 (3): 293-8
117. MacLaren R, Weber LA, Brake H, et al. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion 2005; 45 (9): 1434-42
118. Khan AZ, Parry JM, Crowley WF, et al. Recombinant factor VIIa for the treatment of severe postoperative and traumatic hemorrhage. Am J Surg 2005; 189 (3): 331-4
119. Stein DM, Dutton RP, O'Connor J, et al. Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma Inj Infect Crit Care 2005; 59 (3): 609-15
120. Meng ZH, Wolberg AS, Monroe DM, et al. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003 Nov; 55 (5): 886-91
121. Clark AD, Gordon WC, Walker ID, et al. 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 2004 Feb; 86 (2): 120-4
122. Bowles KM, Callaghan CJ, Taylor AL, et al. Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage. Br J Anaesth 2006 Oct; 97 (4): 476-81
123. Biss TT, Hanley JP. Recombinant activated factor VII (rFVIIa/ NovoSeven) in intractable haemorrhage: use of a clinical scoring system to predict outcome. Vox Sang 2006 Jan; 90 (1): 45-52
124. Morris S, Ridley S, Munro V, et al. Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United Kingdom. Anaesthesia 2007; 62 (1): 43-52
125. Earnshaw SR, Joshi AV, Wilson MR, et al. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke 2006; 37 (11): 2751-8
126. Loudon B, Smith MP. Recombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: a pharmacoeconomic evaluation. Intern Med J 2005 Aug; 35 (8): 463-7
127. Odeyemi IAO, Friederich PW, Levi M. Economic impact of recombinant activated factor VII in the control of bleeds associated with abdominal prostatectomy. J Med Econ 2004; 7 (107-115): 107-15